219 related articles for article (PubMed ID: 11719225)
1. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.
Palmer RE; Kotsianti A; Cadman B; Boyd T; Gerald W; Haber DA
Curr Biol; 2001 Nov; 11(22):1805-9. PubMed ID: 11719225
[TBL] [Abstract][Full Text] [Related]
2. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin.
Lee SB; Huang K; Palmer R; Truong VB; Herzlinger D; Kolquist KA; Wong J; Paulding C; Yoon SK; Gerald W; Oliner JD; Haber DA
Cell; 1999 Sep; 98(5):663-73. PubMed ID: 10490105
[TBL] [Abstract][Full Text] [Related]
3. Integration of Cistromic and Transcriptomic Analyses Identifies Nphs2, Mafb, and Magi2 as Wilms' Tumor 1 Target Genes in Podocyte Differentiation and Maintenance.
Dong L; Pietsch S; Tan Z; Perner B; Sierig R; Kruspe D; Groth M; Witzgall R; Gröne HJ; Platzer M; Englert C
J Am Soc Nephrol; 2015 Sep; 26(9):2118-28. PubMed ID: 25556170
[TBL] [Abstract][Full Text] [Related]
4. A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development.
Natoli TA; Liu J; Eremina V; Hodgens K; Li C; Hamano Y; Mundel P; Kalluri R; Miner JH; Quaggin SE; Kreidberg JA
J Am Soc Nephrol; 2002 Aug; 13(8):2058-67. PubMed ID: 12138137
[TBL] [Abstract][Full Text] [Related]
5. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development.
Kim HS; Kim MS; Hancock AL; Harper JC; Park JY; Poy G; Perantoni AO; Cam M; Malik K; Lee SB
J Biol Chem; 2007 Jun; 282(22):16278-87. PubMed ID: 17430890
[TBL] [Abstract][Full Text] [Related]
7. New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes.
Morrison AA; Viney RL; Saleem MA; Ladomery MR
Am J Physiol Renal Physiol; 2008 Jul; 295(1):F12-7. PubMed ID: 18385267
[TBL] [Abstract][Full Text] [Related]
8. Impaired transcription factor interplay in addition to advanced glycation end products suppress podocalyxin expression in high glucose-treated human podocytes.
Drossopoulou GI; Tsotakos NE; Tsilibary EC
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F594-603. PubMed ID: 19605546
[TBL] [Abstract][Full Text] [Related]
9. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis.
Guo JK; Menke AL; Gubler MC; Clarke AR; Harrison D; Hammes A; Hastie ND; Schedl A
Hum Mol Genet; 2002 Mar; 11(6):651-9. PubMed ID: 11912180
[TBL] [Abstract][Full Text] [Related]
10. A murine model of Denys-Drash syndrome reveals novel transcriptional targets of WT1 in podocytes.
Ratelade J; Arrondel C; Hamard G; Garbay S; Harvey S; Biebuyck N; Schulz H; Hastie N; Pontoglio M; Gubler MC; Antignac C; Heidet L
Hum Mol Genet; 2010 Jan; 19(1):1-15. PubMed ID: 19797313
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.
Maheswaran S; Englert C; Zheng G; Lee SB; Wong J; Harkin DP; Bean J; Ezzell R; Garvin AJ; McCluskey RT; DeCaprio JA; Haber DA
Genes Dev; 1998 Apr; 12(8):1108-20. PubMed ID: 9553041
[TBL] [Abstract][Full Text] [Related]
12. Wilms tumor and the WT1 gene.
Lee SB; Haber DA
Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
[TBL] [Abstract][Full Text] [Related]
13. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
14. PINCH1 is transcriptional regulator in podocytes that interacts with WT1 and represses podocalyxin expression.
Wang D; Li Y; Wu C; Liu Y
PLoS One; 2011 Feb; 6(2):e17048. PubMed ID: 21390327
[TBL] [Abstract][Full Text] [Related]
15. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
Yang Y; Jeanpierre C; Dressler GR; Lacoste M; Niaudet P; Gubler MC
Am J Pathol; 1999 Jan; 154(1):181-92. PubMed ID: 9916932
[TBL] [Abstract][Full Text] [Related]
16. RNA binding by the Wilms tumor suppressor zinc finger proteins.
Caricasole A; Duarte A; Larsson SH; Hastie ND; Little M; Holmes G; Todorov I; Ward A
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7562-6. PubMed ID: 8755514
[TBL] [Abstract][Full Text] [Related]
17. A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus.
Srichai MB; Konieczkowski M; Padiyar A; Konieczkowski DJ; Mukherjee A; Hayden PS; Kamat S; El-Meanawy MA; Khan S; Mundel P; Lee SB; Bruggeman LA; Schelling JR; Sedor JR
J Biol Chem; 2004 Apr; 279(14):14398-408. PubMed ID: 14736876
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
[TBL] [Abstract][Full Text] [Related]
19. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.
Schumacher VA; Jeruschke S; Eitner F; Becker JU; Pitschke G; Ince Y; Miner JH; Leuschner I; Engers R; Everding AS; Bulla M; Royer-Pokora B
J Am Soc Nephrol; 2007 Mar; 18(3):719-29. PubMed ID: 17267748
[TBL] [Abstract][Full Text] [Related]
20. Role for first zinc finger of WT1 in DNA sequence specificity: Denys-Drash syndrome-associated WT1 mutant in ZF1 enhances affinity for a subset of WT1 binding sites.
Wang D; Horton JR; Zheng Y; Blumenthal RM; Zhang X; Cheng X
Nucleic Acids Res; 2018 May; 46(8):3864-3877. PubMed ID: 29294058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
